Prior Oral Anticoagulant Use May Influence Stroke, Bleeding Risk in AF
Exploring the Future of Anticoagulant Treatments for Atrial Fibrillation New Insights from OCEANIC-AF Study The recent findings from the Oral Factor 11a Inhibitor Asundexian as Novel Antithrombotic–Atrial Fibrillation (OCEANIC-AF) study opened up new possibilities in treating atrial fibrillation (AF) patients. Atrial fibrillation is a common heart condition led by irregular heartbeats, increasing the risk of … Read more